The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
Genome-wide burden survival tests for patients with metastatic prostate cancer on androgen receptor-targeted therapies in the Million Veterans Program dataset. This is an ASCO Meeting Abstract from ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
The median overall survival was 38.21 months with radium-223 plus enzalutamide and 32.62 months with enzalutamide alone. For patients with metastatic castration-resistant prostate cancer (mCRPC) with ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...
The addition of pembrolizumab (Keytruda) to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) did not improve overall or radiographic progression-free survival versus ...
Enhanced antitumor activity was seen with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate ...
ONCT-534 showed a well-tolerated safety profile in mCRPC patients on a twice-daily dosing schedule, with no grade 3 or higher toxicities reported. Despite trial discontinuation, ONCT-534 demonstrated ...
SAN FRANCISCO -- In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus ...
TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...
(RTTNews) - Corvus Pharmaceuticals Inc. (CRVS) announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results